Flash therapy is a non-invasive high-dose treatment delivered at ultra-high speeds (less than one second), in one to three sessions. Varian and two clinical partners— Maryland Proton Treatment Center and Cincinnati Children's/UC Health Proton Therapy Center—have conducted preclinical, translational research and the results were encouraging enough for us to take the step of forming a FlashForward™ Consortium that is focused on preclinical research, clinical implementation and advocacy efforts.
The current FlashForward Consortium members are:
- The Christie Proton Therapy Centre
- Cincinnati Children's/UC Health Proton Therapy Center
- Danish Centre for Particle Therapy
- Emory Proton Therapy Center
- Holland Particle Therapy Centre
- New York Proton Center
- Paul Scherrer Institute
- Penn Medicine
- Proton International at the University of Alabama at Birmingham
- South Florida Proton Therapy Institute
- Sylvester Comprehensive Cancer Center Proton Therapy
- University College London
- University of Maryland Department of Radiation Oncology
- VU University Medical Center Amsterdam
Flash therapy represents an exciting and potentially promising new direction in the treatment of cancer. Working groups in the FlashForward Consortium will help identify preclinical study design for understanding this therapy, develop and share protocols, and assist with regulatory and advocacy efforts.
"We are very excited about the initial preclinical research that has been done on Flash therapy and the potential for a major breakthrough in cancer care," said Dee Khuntia, MD, chief medical officer at Varian. "Varian's preclinical results have shown significantly reduced toxicities to healthy tissues while maintaining excellent tumor control and thereby enhancing the therapeutic ratio. We look forward to working closely with the members of the FlashForward Consortium and taking a big step forward in the fight against cancer."
"As a world leader in radiation protection science we are excited about the early results. We applaud Varian for its innovative approach and partnering with the Maryland Proton Treatment Center on this groundbreaking research," said William F. Regine, MD, FACR, FACRO, Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology University of Maryland School of Medicine, Executive Director, Maryland Proton Treatment Center.
The information captured herein represents the genuine experience of the attributed individuals and may not necessarily represent the views of Varian or the above referenced institutions. Individuals were not compensated for their participation.